Cargando…
Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?
Evidence-based guidelines have undergone an incredible transformation over the last number of years. Significant advances include explicit linkages of systematic evidence summaries to the strength and direction of recommendations, consideration of all patient-important factors, transparent reporting...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748604/ https://www.ncbi.nlm.nih.gov/pubmed/26860831 http://dx.doi.org/10.1186/s12916-016-0563-0 |
_version_ | 1782415150678016000 |
---|---|
author | Rochwerg, Bram Schünemann, Holger J. Raghu, Ganesh |
author_facet | Rochwerg, Bram Schünemann, Holger J. Raghu, Ganesh |
author_sort | Rochwerg, Bram |
collection | PubMed |
description | Evidence-based guidelines have undergone an incredible transformation over the last number of years. Significant advances include explicit linkages of systematic evidence summaries to the strength and direction of recommendations, consideration of all patient-important factors, transparent reporting of the recommendation generation process including conflict of interest management strategies and the production of clinical practice guidelines which use simple and clear language. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology provides a framework for guideline development and was employed to produce the recently published ATS/ERS/JRS/ALAT update on treatment for idiopathic pulmonary fibrosis (IPF). Herein we discuss the advantages of using an evidence-based approach for guideline development using the IPF process and resultant document as an example. |
format | Online Article Text |
id | pubmed-4748604 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47486042016-02-11 Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development? Rochwerg, Bram Schünemann, Holger J. Raghu, Ganesh BMC Med Commentary Evidence-based guidelines have undergone an incredible transformation over the last number of years. Significant advances include explicit linkages of systematic evidence summaries to the strength and direction of recommendations, consideration of all patient-important factors, transparent reporting of the recommendation generation process including conflict of interest management strategies and the production of clinical practice guidelines which use simple and clear language. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology provides a framework for guideline development and was employed to produce the recently published ATS/ERS/JRS/ALAT update on treatment for idiopathic pulmonary fibrosis (IPF). Herein we discuss the advantages of using an evidence-based approach for guideline development using the IPF process and resultant document as an example. BioMed Central 2016-02-10 /pmc/articles/PMC4748604/ /pubmed/26860831 http://dx.doi.org/10.1186/s12916-016-0563-0 Text en © Rochwerg et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Commentary Rochwerg, Bram Schünemann, Holger J. Raghu, Ganesh Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development? |
title | Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development? |
title_full | Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development? |
title_fullStr | Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development? |
title_full_unstemmed | Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development? |
title_short | Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development? |
title_sort | idiopathic pulmonary fibrosis – clinical management guided by the evidence-based grade approach: what arguments can be made against transparency in guideline development? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748604/ https://www.ncbi.nlm.nih.gov/pubmed/26860831 http://dx.doi.org/10.1186/s12916-016-0563-0 |
work_keys_str_mv | AT rochwergbram idiopathicpulmonaryfibrosisclinicalmanagementguidedbytheevidencebasedgradeapproachwhatargumentscanbemadeagainsttransparencyinguidelinedevelopment AT schunemannholgerj idiopathicpulmonaryfibrosisclinicalmanagementguidedbytheevidencebasedgradeapproachwhatargumentscanbemadeagainsttransparencyinguidelinedevelopment AT raghuganesh idiopathicpulmonaryfibrosisclinicalmanagementguidedbytheevidencebasedgradeapproachwhatargumentscanbemadeagainsttransparencyinguidelinedevelopment |